title: Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
authors.affiliation: California Pacific Center for Melanoma Research and Treatment, San Francisco, CA, USA.
authors.forename: David R
authors.initials: DR
authors.lastname: Minor
authors.affiliation: Division of Hematology-Oncology, Vanderbilt University, Nashville, TN, USA.
authors.forename: Igor
authors.initials: I
authors.lastname: Puzanov
authors.affiliation: Department of Medicine, Memorial-Sloan Cancer Institute, New York, NY, USA.
authors.forename: Margaret K
authors.initials: MK
authors.lastname: Callahan
authors.affiliation: Oncology Research and Development, Glaxo Smith Kline, Collegeville, PA, USA.
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Hug
authors.affiliation: Oncology Research and Development, Glaxo Smith Kline, Collegeville, PA, USA.
authors.forename: Axel
authors.initials: A
authors.lastname: Hoos
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003092:Colitis / Q000139:chemically induced*; D003106:Colon / Q000187:drug effects; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D007167:Immunotherapy / Q000379:methods; D000074324:Ipilimumab; D008545:Melanoma / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D010091:Oximes / Q000008:administration & dosage* / Q000009:adverse effects; D011728:Pyridones / Q000008:administration & dosage* / Q000009:adverse effects; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000009:adverse effects; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D007093:Imidazoles; D000074324:Ipilimumab; D010091:Oximes; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; C561627:dabrafenib